Alvocidib
The free base form of a synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity. [ ]
Term info
Alvocidib
- (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one
- ALVOCIDIB
- Alvocidib
- Alvocidib Freebase
- Flavopiridol
- alvocidib
- flavopiridol
NCIT_C116978, NCIT_C63923, NCIT_C128784, NCIT_C157711, NCIT_C116977, NCIT_C157712
146426-40-6
C21H20ClNO5
CTRP, FDA
Alvocidib
45AD6X575G
http://purl.obolibrary.org/obo/NCIT_C1571
http://purl.obolibrary.org/obo/NCIT_C17767
Alvocidib_Freebase
Alvocidib
Pharmacologic Substance, Organic Chemical
C0174903
C74940
Term relations
- Cyclin-Dependent Kinase Inhibitor
- Chemical_Or_Drug_Has_Physiologic_Effect some Gene Regulation Process
- Chemical_Or_Drug_Has_Mechanism_Of_Action some Enzyme Inhibition
- Chemical_Or_Drug_Has_Physiologic_Effect some Positive Regulation of Apoptosis
- Chemical_Or_Drug_Has_Physiologic_Effect some Protein Phosphorylation Inhibition
- Chemical_Or_Drug_Has_Physiologic_Effect some Negative Regulation of G1 Phase
- Chemical_Or_Drug_Affects_Gene_Product some Cyclin-Dependent Kinase
- Chemical_Or_Drug_Has_Physiologic_Effect some Negative Regulation of G2 to M Transition